AN INTENTIONALLY DESIGNED, HIGH- QUALITY PRODUCT TO DRIVE PATIENT SATISFACTION
RESULTS
Demonstrated safety in 5 clinical studies, with >2100 subjects
SATISFACTION
See the real results that keep patients satisfied
PRODUCT
See how Jeuveau® is different by design
Jeuveau® (prabotulinumtoxinA-xvfs) is different by design1,2 with a modern manufacturing process that helps you deliver precise, long-lasting, natural-looking results.3-6
Every botulinum neurotoxin is unique and not interchangeable. Jeuveau cannot be compared or converted into units of any other botulinum toxin product.1,2
EVERY NEUROTOXIN
HAS ITS OWN PERSONALITY
PRECISE PRODUCT
Jeuveau is a 900 kDa neurotoxin designed with purpose in California.1 Our unique manufacturing combines vacuum-dried processing with proprietary Hi-Pure™ technology, resulting in ≥95% product purity and a diffusion profile that supports results as you intend them.3,6
THE POWER
OF PRECISION
IS IN YOUR SKILLED HANDS
When used in conjunction with intramuscular injection for glabellar lines,1,4 Jeuveau offers:
A precise, tight field of effect that puts control in your hands1
Natural-looking results, exactly where you want them6,7
Consistent outcomes, for consistently satisfied patients6,7,*
*87% of injectors consider Jeuveau to be a precise product when injected intramuscularly.8
RESULTS PRECISELY
WHERE YOU WANT THEM
In 2 clinical trials, Jeuveau demonstrated low rates of eyelid ptosis7
EV-001 and EV-002 were phase 3, randomized, multicenter, double-blind placebo-controlled US trials designed to assess the superiority of Jeuveau vs placebo in the treatment of moderate to severe glabellar lines in adults.
IT'S ALL IN YOUR PRECISE TECHNIQUE
Your skilled technique can elevate results from good to great. Jeuveau is a precision product that requires a precise injection technique, beginning with a thorough understanding and assessment of functional anatomy.4
If you had an amount of Jeuveau equivalent to the size of a grain of salt, it could fill approximately
Imagine the precision in the manufacturing process
8,9,*
UNIQUE
RESULTS THAT SPEAK VOLUMES
Jeuveau demonstrated a proven safety profile in 5 clinical studies included in the Transparency Clinical Program:
- 2 phase 3 pivotal studies (n=645)7
- The largest head-to-head aesthetic EU/Canada phase 3 trial vs Botox® Cosmetic (n=540)5,*
- 2 long-term safety studies (n=922)11,12,†
In 2 US pivotal phase 3 studies, 68% and 70% of Jeuveau patients with moderate to severe frown lines had a 2-grade or better physician- and patient-rated improvement (none or mild frown lines) at Day 30, compared to 1% for placebo.
*Jeuveau demonstrated non-inferiority to Botox Cosmetic in the treatment of moderate to severe glabellar lines in adults based on a GLS score of 0 or 1 at maximum frown on Day 30 by investigator assessment.
†Jeuveau demonstrated a proven safety profile, with no serious drug-related adverse events in clinical trials.
PROVEN RESULTS
FACE OFF AGAINST BOTOX COSMETIC
We're so confident in our results, we put Jeuveau® to the test against the legacy neurotoxin brand, Botox® Cosmetic.5
PROVEN RESULTS IN THE LARGEST HEAD-TO-HEAD STUDY OF ITS KIND
In the largest head-to-head, EU/Canada double-blinded, randomized phase 3 study of moderate-to-severe glabellar lines, Jeuveau demonstrated substantially similar results vs Botox Cosmetic (EVB-003 non-inferiority study).5,*
GLS score of 0 or 1 at maximum frown on day 30 by investigator assessment
*A non-inferiority study is conducted to show that the effect of a treatment is not worse than the original treatment.
Botox® Cosmetic is a registered trademark of Allergan, Inc.
®
saw significant improvement
in the look of their frown
lines5
(n=235)
saw significant improvement
in the look of their frown
lines5
(n=244)
FAST ACTING, LONG LASTING
SECONDARY ENDPOINTS INCLUDED
In EVB-003, patients with GLS scores of 0 or 1 by investigator assessment at day 30: 87.2% Jeuveau vs 4.2% placebo.
Comparisons against placebo after day 30 or based on a 1-grade improvement may not be clinically meaningful.
EXPLORATORY ENDPOINTS
Investigator and subject assessment of GLS ≥1-point improvement at maximum frown at days 2, 14, 30, 90, 120, and 150.5
exploratory endpoints numerically favored Jeuveau® vs Botox® Cosmetic 5
In EVB-003, patients with GLS scores of 0 or 1 by investigator assessment at day 30: 87.2% Jeuveau vs 4.2% placebo.
Comparisons against placebo after day 30 or based on a 1-grade improvement may not be clinically meaningful.
ET=early termination.
GLS=glabellar line scale.
Botox® Cosmetic is a registered trademark of Allergan, Inc.
JEUVEAU’S EFFECTIVENESS HAS BEEN STUDIED IN MULTIPLE GROWING PATIENT POPULATIONS
Post hoc analyses demonstrate Jeuveau’s effectiveness in different patient populations. This includes males and Millennials—2 segments that are driving growth in the facial injectable market.15,16
In males
In a post hoc analyses of pivotal studies, the head-to-head study against Botox Cosmetic, more men treated with Jeuveau achieved a GLS score improvement at every single visit by investigator assessment (absolute overall mean difference of 10.1%, but not statistically significant).5,13
In Millennials
In a post hoc analyses of pivotal studies EV-001 and EV-002 (n=65), 100% of millennials achieved a ≥1-point improvement on the GLS at maximum frown by investigator assessment.7,14
CLICK HERE TO SEE THE FULL
GLS=glabellar line scale
AT MAXIMUM FROWN. ACTUAL PATENT. RESULTS MAY VARY.
FAST-ACTING,
LONG-LASTING RESULTS
In a phase 3 clinical study, majority of patients experienced onset as early as day 2 and visible results, even at 4 months5.
PATIENT SATISFACTION
HIGH PATIENT SATISFACTION RATINGS
In a clinical trial,
of Jeuveau patients rated themselves as improved or much improved at day 305
In a quantitative consumer survey:
(n=424)
*Somewhat to extremely likely (top 2 on a 5-point scale).